0 3 Ras Ras NNP 4 12 oncogene oncogene NN 13 27 transformation transformation NN 28 30 of of IN 31 36 human human JJ 37 38 B B NNP 39 51 lymphoblasts lymphoblast NNS 52 54 is be VBZ 55 65 associated associate VBN 66 70 with with IN 71 81 lymphocyte lymphocyte NN 82 92 activation activation NN 93 96 and and CC 97 101 with with IN 102 103 a a DT 104 109 block block NN 110 112 of of IN 113 128 differentiation differentiation NN 128 129 . . . 131 134 The the DT 135 141 p21ras p21ras NN 142 147 small small JJ 148 151 GTP GTP NNP 152 159 binding binding NN 160 168 proteins protein NNS 169 180 participate participate VBP 181 183 in in IN 184 190 signal signal NN 191 203 transduction transduction NN 204 208 from from IN 209 213 cell cell NN 214 221 surface surface NN 222 231 receptors receptor NNS 232 235 and and CC 236 242 affect affect VB 243 253 neoplastic neoplastic JJ 254 268 transformation transformation NN 269 272 and and CC 273 284 development development NN 285 287 in in IN 288 292 many many JJ 293 302 different different JJ 303 307 cell cell NN 308 313 types type NNS 313 314 . . . 315 317 In in IN 318 321 the the DT 322 329 present present JJ 330 335 study study NN 335 336 , , , 337 339 we we PRP 340 348 examined examine VBD 349 352 the the DT 353 365 relationship relationship NN 366 373 between between IN 374 377 ras ras NN 378 392 transformation transformation NN 393 396 and and CC 397 412 differentiation differentiation NN 413 415 of of IN 416 421 human human JJ 422 423 B B NNP 424 435 lymphocytes lymphocyte NNS 435 436 . . . 437 439 We we PRP 440 444 show show VBP 445 449 that that IN 450 453 the the DT 454 466 constitutive constitutive JJ 467 477 expression expression NN 478 480 of of IN 481 484 the the DT 485 488 T24 T24 NNP 489 495 Ha-ras Ha-ras NNP 496 504 oncogene oncogene NN 505 507 in in IN 508 524 EBV-immortalized ebv-immortalized JJ 525 526 B B NNP 527 539 lymphoblasts lymphoblast NNS 540 543 was be VBD 544 554 associated associate VBN 555 559 with with IN 560 563 the the DT 564 573 induction induction NN 574 576 of of IN 577 580 the the DT 581 592 interleukin interleukin NN 593 594 2 2 CD 595 603 receptor receptor NN 604 609 alpha alpha NN 610 617 subunit subunit NN 617 618 , , , 619 623 with with IN 624 626 an an DT 627 635 impaired impaired JJ 636 650 immunoglobulin immunoglobulin NN 651 655 gene gene NN 656 666 expression expression NN 666 667 , , , 668 675 altered altered JJ 676 684 adhesion adhesion NN 685 695 properties property NNS 696 699 and and CC 700 709 increased increase VBN 710 718 survival survival NN 719 721 in in IN 722 732 serum-free serum-free JJ 733 739 medium medium NN 739 740 . . . 741 746 Since since IN 747 756 induction induction NN 757 759 of of IN 760 763 the the DT 764 768 IL-2 il-2 NN 769 777 receptor receptor NN 778 783 alpha alpha NN 784 791 subunit subunit NN 792 794 is be VBZ 795 796 a a DT 797 805 hallmark hallmark NN 806 808 of of IN 809 819 lymphocyte lymphocyte NN 820 830 activation activation NN 830 831 , , , 832 834 we we PRP 835 842 suggest suggest VBP 843 847 that that IN 848 854 p21ras p21ras NN 855 864 naturally naturally RB 865 873 triggers trigger VBZ 874 875 B B NNP 876 880 cell cell NN 881 891 activation activation NN 891 892 . . . 893 896 The the DT 897 912 ras-transformed ras-transformed JJ 913 924 lymphocytes lymphocyte NNS 925 934 displayed display VBD 935 936 a a DT 937 942 fully fully RB 943 953 functional functional JJ 954 959 IL-2r IL-2r NNP 959 960 , , , 961 963 as as IN 964 972 assessed assess VBN 973 975 by by IN 976 981 c-fos c-fos NN 982 991 induction induction NN 992 1001 following follow VBG 1002 1011 treatment treatment NN 1012 1016 with with IN 1017 1021 IL-2 il-2 NN 1021 1022 ; ; : 1023 1035 nevertheless nevertheless RB 1035 1036 , , , 1037 1041 they they PRP 1042 1046 were be VBD 1047 1050 not not RB 1051 1057 growth growth NN 1058 1068 stimulated stimulate VBN 1069 1071 by by IN 1072 1076 this this DT 1077 1087 lymphokine lymphokine NN 1087 1088 . . . 1089 1092 The the DT 1093 1102 decreased decrease VBN 1103 1113 expression expression NN 1114 1116 of of IN 1117 1131 immunoglobulin immunoglobulin NN 1132 1137 genes gene NNS 1138 1147 indicates indicate VBZ 1148 1152 that that IN 1153 1156 the the DT 1157 1160 ras ras NN 1161 1169 oncogene oncogene NN 1170 1176 blocks block VBZ 1177 1185 terminal terminal JJ 1186 1201 differentiation differentiation NN 1202 1204 to to TO 1205 1211 plasma plasma NN 1212 1217 cells cell NNS 1217 1218 , , , 1219 1227 possibly possibly RB 1228 1230 by by IN 1231 1241 inhibiting inhibit VBG 1242 1245 the the DT 1246 1254 activity activity NN 1255 1257 of of IN 1258 1277 lymphocyte-specific lymphocyte-specific JJ 1278 1291 transcription transcription NN 1292 1299 factors factor NNS 1299 1300 . . . 1301 1309 Somewhat somewhat RB 1310 1322 unexpectedly unexpectedly RB 1322 1323 , , , 1324 1327 the the DT 1328 1340 constitutive constitutive JJ 1341 1347 p21ras p21ras NN 1348 1356 activity activity NN 1357 1360 did do VBD 1361 1364 not not RB 1365 1370 cause cause VB 1371 1373 an an DT 1374 1383 increased increase VBN 1384 1387 DNA dna NN 1388 1395 binding binding NN 1396 1398 of of IN 1399 1412 transcription transcription NN 1413 1420 factors factor NNS 1421 1425 PEA1 pea1 NN 1426 1427 ( ( ( 1427 1430 AP1 AP1 NNP 1430 1431 ) ) ) 1431 1432 , , , 1433 1437 PEA3 PEA3 NNP 1437 1438 , , , 1439 1444 Oct-2 Oct-2 NNP 1445 1447 or or CC 1448 1453 NF-kB NF-kB NNP 1453 1454 . . .